摘要
MicroRNAs(miRNAs)是一类小型非编码单链RNA分子,它通过与靶mRNA的3''非翻译区的直接作用阻碍蛋白质的合成。有趣的是,通常阻断癌细胞的上皮间质转化(EMT)而表现出肿瘤抑制的癌症中,miR-200c通常失调。然而,各种肿瘤组织中miR-200c的升高与该miRNA的肿瘤抑制作用相矛盾。本文综述了乳腺、卵巢、前列腺、子宫内膜、肺、结肠、胰腺肿瘤中参与miR-200c的内源性水平调控的分子机制以及其对癌细胞的增殖和EMT表型的调控作用。除此之外,本文还讨论了肿瘤组织或血液循环中miR-200c的水平异常是否可作为生物标志物。重要的是,本文对miR-200c水平如何用于预测癌症疗法的有效性进行了讨论。越来越多的证据表明,单独使用miR-200c很难治愈癌症患者,但miR-200c与抗增殖药物结合后可以更好地预防肿瘤侵袭以及原发性和转移性肿瘤的增殖。本文还指出肿瘤微环境可能影响miR-200c表达的表观遗传沉默。
关键词: 生物标志物,上皮间质转化,microRNA,miR-200c,肿瘤微环境,肿瘤抑制剂。
图形摘要
Current Drug Targets
Title:A Comprehensive Review on miR-200c, A Promising Cancer Biomarker with Therapeutic Potential
Volume: 16 Issue: 12
Author(s): Suresh Kumar, Alo Nag and Chandi C. Mandal
Affiliation:
关键词: 生物标志物,上皮间质转化,microRNA,miR-200c,肿瘤微环境,肿瘤抑制剂。
摘要: MicroRNAs (miRNAs) are small single stranded non coding RNA molecules (~22 nucleotides) which impede protein production by directly interacting with 3’untranslated regions of the target mRNAs. Interestingly, miR-200c is often dysregulated in various cancers that normally exhibits tumor suppressive behavior by blocking epithelial to mesenchymal transition (EMT) of cancer cells. However, elevation of miR-200c in various cancer tissues contradicts the tumor suppressive role of this microRNA. This review addresses the molecular mechanisms involved in the regulation of the endogenous level of miR-200c in various cancers such as breast, ovarian, prostate, endometrial, lungs, colon, pancreatic, etc. and its differential role in regulation of proliferation and EMT phenotype of cancer cells. Further, this review discusses whether abnormal level of miR-200c in cancer tissues or in blood circulation can be used as a biomarker. Importantly, how the level of miR-200c can be used to predict the effectiveness of the cancer therapy is also discussed. Accumulating evidences suggest that use of miR-200c alone may not be sufficient for treatment of cancer patients, but the combination of miR-200c with an anti-proliferating drug could be a better choice to prevent invasiveness of cancers as well as tumor growth both in primary and in metastatic sites. This article also proposes that the tumor microenvironment may have a role in influencing epigenetic silencing of miR-200c expression.
Export Options
About this article
Cite this article as:
Suresh Kumar, Alo Nag and Chandi C. Mandal , A Comprehensive Review on miR-200c, A Promising Cancer Biomarker with Therapeutic Potential, Current Drug Targets 2015; 16 (12) . https://dx.doi.org/10.2174/1389450116666150325231419
DOI https://dx.doi.org/10.2174/1389450116666150325231419 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Processed Foods, Dysbiosis, Systemic Inflammation, and Poor Health
Current Nutrition & Food Science Cancer Metastasis: Characterization and Identification of the Behavior of Metastatic Tumor Cells and the Cell Adhesion Molecules, including Carbohydrates
Current Drug Targets - Cardiovascular & Hematological Disorders New Features in the Treatment of Androgen-Independent Prostate Cancer
Current Pharmaceutical Design Adenosine A<sub>3</sub> Receptor: A promising therapeutic target in cardiovascular disease
Current Cardiology Reviews CD147 Interacts with NDUFS6 in Regulating Mitochondrial Complex I Activity and the Mitochondrial Apoptotic Pathway in Human Malignant Melanoma Cells
Current Molecular Medicine The Use of the Bone Seeking Radiopharmaceutical 153-Samarium-EDTMP as an Adjuvant Treatment for Osteosarcoma: A Review
Current Medical Imaging Signal Transduction Therapy: Challenges to Clinical Trial Design
Current Signal Transduction Therapy Clinical Experiment of Mutant Herpes Simplex Virus HF10 Therapy for Cancer
Current Cancer Drug Targets Modulation of Carbonic Anhydrase 9 (CA9) in Human Brain Cancer
Current Pharmaceutical Design Cathelicidins: Peptides with Antimicrobial, Immunomodulatory, Anti- Inflammatory, Angiogenic, Anticancer and Procancer Activities
Current Protein & Peptide Science Writers and Erasers of Histone Lysine methylation with Clinically Applied Modulators: Promising Target for Cancer Therapy
Current Pharmaceutical Design Targeting FGFR with BGJ398 in Breast Cancer: Effect on Tumor Growth and Metastasis
Current Cancer Drug Targets Bladder Cancer: Innovative Approaches Beyond the Diagnosis
Current Medicinal Chemistry An Overview on Keratinocyte Growth Factor: From the Molecular Properties to Clinical Applications
Protein & Peptide Letters Relative In Vitro Potentials of Parthenolide to Induce Apoptosis and Cell Cycle Arrest in Skin Cancer Cells
Current Drug Discovery Technologies Apoptosis-related BCL2-family Members: Key Players in Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Exosomes Harnessed as Nanocarriers for Cancer Therapy - Current Status and Potential for Future Clinical Applications
Current Molecular Medicine Overcoming Endocrine Resistance in Breast Cancer
Current Cancer Drug Targets The Role of Melatonin in Multiple Sclerosis, Huntington's Disease and Cerebral Ischemia
CNS & Neurological Disorders - Drug Targets <i>Uncaria tomentosa</i> (Willd. ex Schult.): Focus on Nutraceutical Aspects
Current Bioactive Compounds